FGF2 and myeloid sarcoma: Plasma FGFb was markedly diminished in PP-MS patients when compared to SP-MS (11±10 vs 26±27, p = 0.01), patients undergoing a clinical relapse (11±10 vs 21±11, p = 0.01), or healthy controls (11±10 vs 28±31, p = 0.02) (Fig 3).